{"nctId":"NCT01204671","briefTitle":"Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)","startDateStruct":{"date":"2010-10-04"},"conditions":["Influenza"],"count":4659,"armGroups":[{"label":"GSK2321138A Lot 1 Group","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza vaccine GSK2321138A"]},{"label":"GSK2321138A Lot 2 Group","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza vaccine GSK2321138A"]},{"label":"GSK2321138A Lot 3 Group","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza vaccine GSK2321138A"]},{"label":"Fluarix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: FluarixTM"]},{"label":"GSK2604409A Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Influenza vaccine GSK2604409A"]}],"interventions":[{"name":"Influenza vaccine GSK2321138A","otherNames":[]},{"name":"FluarixTM","otherNames":[]},{"name":"Influenza vaccine GSK2604409A","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female 18 years of age or older at the time of the first vaccination\n* Subjects who the investigator believes can and will comply with the requirements of the protocol.\n* Written informed consent obtained from the subject.\n* Healthy subjects or those with chronic well-controlled disease as established by physical examination before entering into the study.\n* Female subjects of non-childbearing potential may be enrolled in the study.\n* Female subjects of childbearing potential may be enrolled in the study, if the subject:\n* \\- has practiced adequate contraception for 30 days prior to vaccination,\n* \\- and has a negative urine pregnancy test on the day of vaccination,\n* and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of the study vaccine or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.\n* Administration of an influenza vaccine during the 6 months preceding entry into the study.\n* Planned administration / administration of a vaccine not foreseen by the study protocol within 30 days before vaccination and up to Day 21.\n* Any contra-indication to intramuscular administration of the influenza vaccines.\n* History of hypersensitivity/anaphylaxis to a previous dose of influenza vaccine, history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.\n* Any administration of a long-acting immune-modifying drug within 3 months before study start, or planned administration during the study period.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Acute disease and/or fever at the time of enrolment.\n* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.\n* History of Guillain-Barr√© syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.\n* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.\n* History of chronic alcohol consumption and/or drug abuse.\n* Any condition which, in the opinion of the investigator, prevents the subject from participating in the study\n* Pregnant or lactating female.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease","description":"Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. HI antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null},{"groupId":"OG001","value":"15.6","spread":null},{"groupId":"OG002","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"201.1","spread":null},{"groupId":"OG001","value":"218.4","spread":null},{"groupId":"OG002","value":"213.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"38.1","spread":null},{"groupId":"OG002","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"314.7","spread":null},{"groupId":"OG001","value":"298.2","spread":null},{"groupId":"OG002","value":"340.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"73.6","spread":null},{"groupId":"OG002","value":"71.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"404.6","spread":null},{"groupId":"OG001","value":"393.8","spread":null},{"groupId":"OG002","value":"258.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.4","spread":null},{"groupId":"OG001","value":"100.9","spread":null},{"groupId":"OG002","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"601.8","spread":null},{"groupId":"OG001","value":"386.6","spread":null},{"groupId":"OG002","value":"582.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroconverted Subjects Against 4 Strains of Influenza Disease","description":"A seroconverted subject was a vaccinated subject who had either a pre-vaccination hemagglutination inhibition (HI) antibody titer \\< 1:10 and a post-vaccination titer above or equal (\\>=) 1:40, or a pre-vaccination HI antibody titer \\>= 1:10 and at least a 4-fold increase in post-vaccination HI antibody titer. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1396","spread":null},{"groupId":"OG001","value":"467","spread":null},{"groupId":"OG002","value":"425","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1287","spread":null},{"groupId":"OG001","value":"398","spread":null},{"groupId":"OG002","value":"371","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1046","spread":null},{"groupId":"OG001","value":"335","spread":null},{"groupId":"OG002","value":"252","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1112","spread":null},{"groupId":"OG001","value":"276","spread":null},{"groupId":"OG002","value":"313","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects Against 4 Strains of Influenza Disease","description":"A seropositive subject was a vaccinated subject with hemagglutination inhibition (HI) antibody titer above or equal (\\>=) the reference cut-off value of 1:10. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"967","spread":null},{"groupId":"OG001","value":"352","spread":null},{"groupId":"OG002","value":"291","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1738","spread":null},{"groupId":"OG001","value":"586","spread":null},{"groupId":"OG002","value":"514","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1416","spread":null},{"groupId":"OG001","value":"488","spread":null},{"groupId":"OG002","value":"425","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1783","spread":null},{"groupId":"OG001","value":"594","spread":null},{"groupId":"OG002","value":"528","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1541","spread":null},{"groupId":"OG001","value":"511","spread":null},{"groupId":"OG002","value":"452","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1795","spread":null},{"groupId":"OG001","value":"601","spread":null},{"groupId":"OG002","value":"518","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1554","spread":null},{"groupId":"OG001","value":"525","spread":null},{"groupId":"OG002","value":"457","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1794","spread":null},{"groupId":"OG001","value":"597","spread":null},{"groupId":"OG002","value":"532","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against 4 Strains of Influenza Disease","description":"A seroprotected subject was a vaccinated subject who had hemagglutination inhibition (HI) antibody titer above or equal (\\>=) 1:40. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"514","spread":null},{"groupId":"OG001","value":"167","spread":null},{"groupId":"OG002","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1651","spread":null},{"groupId":"OG001","value":"558","spread":null},{"groupId":"OG002","value":"495","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"965","spread":null},{"groupId":"OG001","value":"353","spread":null},{"groupId":"OG002","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1751","spread":null},{"groupId":"OG001","value":"583","spread":null},{"groupId":"OG002","value":"517","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1423","spread":null},{"groupId":"OG001","value":"477","spread":null},{"groupId":"OG002","value":"412","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1788","spread":null},{"groupId":"OG001","value":"599","spread":null},{"groupId":"OG002","value":"513","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1494","spread":null},{"groupId":"OG001","value":"497","spread":null},{"groupId":"OG002","value":"441","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1792","spread":null},{"groupId":"OG001","value":"595","spread":null},{"groupId":"OG002","value":"532","spread":null}]}]}]},{"type":"SECONDARY","title":"Increase in Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease","description":"Increase in hemagglutination inhibition (HI) antibodies is presented in terms of mean geometric increase (MGI), defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer , expressed using \"fold increase\" as unit . Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.69","spread":null},{"groupId":"OG001","value":"13.92","spread":null},{"groupId":"OG002","value":"14.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.28","spread":null},{"groupId":"OG001","value":"7.84","spread":null},{"groupId":"OG002","value":"9.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.48","spread":null},{"groupId":"OG001","value":"5.37","spread":null},{"groupId":"OG002","value":"3.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.93","spread":null},{"groupId":"OG001","value":"3.84","spread":null},{"groupId":"OG002","value":"5.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms.","description":"Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"377","spread":null},{"groupId":"OG001","value":"362","spread":null},{"groupId":"OG002","value":"357","spread":null},{"groupId":"OG003","value":"369","spread":null},{"groupId":"OG004","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"17","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"21","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Solicited Local Symptoms","description":"Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"1.0","spread":null},{"groupId":"OG004","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature \\[axillary temperature above or equal to (\\>=) 37.5 degrees Celsius (¬∞C)\\]. Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = symptom which prevented normal every day activities. Grade 3 temperature = axillary temperature \\> 39¬∞C. Related = symptom assessed as causally related to study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"154","spread":null},{"groupId":"OG002","value":"171","spread":null},{"groupId":"OG003","value":"185","spread":null},{"groupId":"OG004","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"118","spread":null},{"groupId":"OG003","value":"132","spread":null},{"groupId":"OG004","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"65","spread":null},{"groupId":"OG004","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"35","spread":null},{"groupId":"OG004","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"162","spread":null},{"groupId":"OG002","value":"155","spread":null},{"groupId":"OG003","value":"164","spread":null},{"groupId":"OG004","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"97","spread":null},{"groupId":"OG004","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"104","spread":null},{"groupId":"OG004","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"51","spread":null},{"groupId":"OG003","value":"61","spread":null},{"groupId":"OG004","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"172","spread":null},{"groupId":"OG002","value":"156","spread":null},{"groupId":"OG003","value":"195","spread":null},{"groupId":"OG004","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"109","spread":null},{"groupId":"OG003","value":"137","spread":null},{"groupId":"OG004","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"50","spread":null},{"groupId":"OG004","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"30","spread":null},{"groupId":"OG004","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Solicited General Symptoms","description":"Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature \\[defined as axillary temperature above or equal to (‚â•) 37.5 degrees Celsius (¬∞C)\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"1.0","spread":null},{"groupId":"OG004","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"1.0","spread":null},{"groupId":"OG004","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","description":"Unsolicited AEs cover any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 unsolicited AE = unsolicited AE that prevented normal everyday activity Related unsolicited AE = unsolicited AE assessed by the investigator as related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"134","spread":null},{"groupId":"OG003","value":"138","spread":null},{"groupId":"OG004","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"26","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Adverse Events With Medically-attended Events (MAEs)","description":"Medically-attended events (MAEs) refer to non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a MAE was leading to hospitalisation (or met any other serious adverse event criterion), it was reported as serious adverse event. Related MAE = MAE assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"688","spread":null},{"groupId":"OG001","value":"216","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)","description":"Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination. Related SAE = SAE assessed by the investigator as related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"26","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":1012},"commonTop":["Pain","Muscle aches","Fatigue","Headache","Joint pain"]}}}